Forte Research Systems Unveils the Allegro™ Research on Demand Cloud-Based Pr... (rend has led individual sites to take on...)

Forte Research Systems Unveils the Allegro™ Research on Demand Cloud-Based Product Line

Date:11/18/2010

rend has led individual sites to take on more trials. At the same time, while sites are grappling with more trials, the trials are becoming much more complex with a proliferation of procedures and subject eligibility criteria.

In an attempt to be more competitive and efficient in this environment, today's sites are implementing tighter financial management, overseeing regulatory compliance more intensively, striving to achieve status as a preferred partner, and adopting clinical trials management systems (CTMS) to streamline operations and replace paper-based processes.

"When it comes to CTMS, current solutions in the marketplace leave a lot to be desired," said Kalluri.

With what is currently available, sites have to choose between products with bloated functionality and complex interfaces that require up-front investments in infrastructure, have ongoing maintenance and administrative overhead, and have long training cycles with slow user adoption rates.

By contrast, the Allegro product line is built for clinical research operations excellence with no software to install and no systems administration required, real-time visibility into the entire clinical research portfolio, and a user-centric, intuitive interface that is easy to use, virtually eliminating the need for training. With Allegro CTMS@Site, sites can get up and running in a single day.

Founded in 2000 and headquartered in Madison, Wisconsin, Forte Research Systems, Inc. develops clinical and translational research management software. The company's flagship product, the OnCore® system, is the nation's most widely adopted clinical research platform among academic research organizations and cancer centers.

PercipEnz Technologies is now Forte Research Systems. Same company, new name.

SOURCE Forte Research Systems
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
2. ForteBio Announces Launch of Protein G Biosensor for Use on Companys Octet® Instruments
3. Endo Pharmaceuticals Completes Next Step in Regulatory Process for FORTESTA™ for Men With Low Testosterone
4. ForteBio Launches New Dip and Read(TM) Residual Protein A Detection Kit; Introduces Sidekick(TM) Offline Biosensor Immobilization Station for All Octet(R) Instruments
5. FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
6. Neuro Kinetics Receives HHS Therapeutic Discovery Grant to Further Research Into Early Diagnosis of Sports Concussions
7. Access Pharmaceuticals ProLindac™ and CobaCyte™ Oncology Research Displayed at the Innovations in Cancer Prevention and Research Conference, November 17-19, 2010
8. MedImmune Announces Winners of the 5th Annual Respiratory, Inflammation and Autoimmunity Research Abstract Competition
9. CVS Caremark Research Finds Correlation Between Amount of Patient Co-pay and Prescription Abandonment
10. Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco
11. New Peripheral Vascular Device Market Research Data Covering Multiple Geographies Released by Millennium Research Group

Post Your Comments:

(Date:5/19/2013)... May 20, 2013 Whole-cell pertussis vaccines were more ... during a large recent outbreak, according to a new ... pertussis vaccines, also called DTwP, were available from the ... that ultimately led to the development of acellular pertussis ... 1990s, the United States had ...

(Date:5/18/2013)... YORK , May 18, 2013 ... law firm, is investigating potential securities fraud at ... AVEO). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... Company and its executives violated federal securities laws ... the Company,s Phase III drug trials for Tivopath ...

(Date:5/17/2013)... , May 17, 2013 Sorrento Therapeutics, ... its Fast-Track Advanced Technology Small Business Technology Transfer ... of Allergy and Infectious Diseases (NIAID), a division ... the development of novel human antibody therapeutics to ... or Staph) infections, including methicillin-resistant S. ...

Breaking Medicine Technology:Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2 Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3 Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4 Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2 Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2 Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3 Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4

[0] Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak [0] Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm [0] Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases

... today reported one year,survival results from a Phase I/II ... in combination with dacarbazine in,patients with unresectable stage III ... cohort of patients in both the Phase I and,Phase ... the entire patient,set and a 22 month overall mean ...

... (NYSE:,AZN) today announced that the company has submitted ... U.S. Food and Drug,Administration (FDA) for once-daily SEROQUEL ... the treatment of manic,episodes associated with bipolar disorder ... disorder., The bipolar mania submission is based ...

Cached Medicine Technology:AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma 2 AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma 3 AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma 4 AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 2 AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 3 AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 4 AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 5 AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 6 AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression 7

AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression

(Date:5/20/2013)... Horizon NJ Health, New Jersey’s largest Medicaid ... has earned a Commendable Accreditation status from the ... is a wholly owned subsidiary of Horizon Blue Cross ... Plan Accreditation is a nationally recognized program that evaluates ... provide to their members. Health Plan Accreditation performance results ...

(Date:5/20/2013)... May 20, 2013 The American Society ... for Bright Pink®, the organization that empowers young women to ... end of 2012. Thanks to its members, ASCP raised more ... is involved in Relay for Life at the local level. ... he decided to donate. “I was made aware of the ...

(Date:5/20/2013)... New York (PRWEB) May 20, 2013 The ... new study has found that magnetic resonance imaging (MRI) can ... regardless of whether or not patients are experiencing symptoms. ... Journal of Bone & Joint Surgery, MRI detected synovitis ... In patients suffering symptoms due to mechanical causes, the detection ...

(Date:5/20/2013)... , , MONDAY, May 20 (HealthDay News) -- Boys who ... as likely to become obese adults as those who ... new 30-year study shows. Researchers found that men ... index (BMI) and obesity, even if they no longer ... well-off or poor, they tended toward obesity. ...

(Date:5/20/2013)... MONDAY, May 20 (HealthDay News) -- The older vaccine ... late 1990s is more effective than the current version ... who received four shots with the older vaccine -- ... old were significantly less likely to become infected with ... to children who received all of their immunizations with ...

Breaking Medicine News(10 mins):Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2 Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3 Health News:ASCP Members Rally Around Breast and Ovarian Cancer Awareness 2 Health News:ASCP Members Rally Around Breast and Ovarian Cancer Awareness 3 Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 2 Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 3 Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 4 Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 2 Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 3 Health News:Study: Older Whooping Cough Vaccine More Effective 2 Health News:Study: Older Whooping Cough Vaccine More Effective 3

[0] Horizon NJ Health Awarded Commendable Accreditation by NCQA [0] ASCP Members Rally Around Breast and Ovarian Cancer Awareness [0] Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure [0] ADHD in Childhood May Raise Risk for Obesity in Adulthood [0] Study: Older Whooping Cough Vaccine More Effective

... most common breast cancer uses the most efficient, powerful ... that system kills it, researchers report. This method ... patients, particularly those resistant to standard therapies such as ... Human estrogen receptor-positive breast cancer cells thriving in a ...

... The second generation drug-eluting stent, everolimus-eluting stent ... in randomised controlled trials over the first ... earlier studies comparing EES with another first ... only demonstrated the non-inferiority of EES; the ...

... order to meet future demands for new pharmaceuticals, ... is dependent on the ongoing development of effective ... Because they are so versatile, organometallic molecules are ... reagents containing zinc atoms have certain advantages over ...

... , MONDAY, Aug. 29 (HealthDay News) -- Boxing ... encourage their kids to find sports that don,t focus ... Those are conclusions from the new policy statement from ... Society that recommends that pediatricians vigorously oppose children participating ...

... Meeting & OTO EXPO of the American Academy of Otolaryngology ... of ear, nose, and throat doctors in the world, will ... more than 386 scientific research sessions, 468 posters, and several ... a unique opportunity for journalists from around the world to ...

... 28 (HealthDay News) -- Although it may sound sweet ... behavior, similar to arguing or slinging insults, Canadian scientists ... Queens University in Kingston, Ontario, also revealed that differences ... live, play a role in how aggressive their shouting ...

Research aims to starve breast cancer cells Clinical outcomes in PCI patients given sirolimus-eluting and everolimus-eluting stents New salts for chemical soups Pediatric Groups Want to KO Boxing for Kids 2011 AAO-HNSF poster presentations Sweet Sparrow Songs May Actually Be Shouting Matches

... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...

... 5mm AEM Laparoscopic Instruments incorporate a layered ... are shielded and monitored to prevent stray ... instrument caused by insulation failure or capacitive ... protective shield built into all AEM Instruments ...

... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...

... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...

Medicine Products:

Alligator Micro-Grasper Atraumatic Grasper Reddick Grasper Long Dolphin Nose Grasper